CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
The ReSPECT Phase III trial met its primary endpoint, demonstrating that REZZAYO achieved non-inferior fungal-free survival at Day 90 compared to standard antimicrobial regimens in HSCT patients. Results highlighted a favorable safety profile with reduced toxicity-related discontinuations and drug-drug interactions, supporting the drug's differentiation in this high-risk population.
Key figures
- Drug Name
- REZZAYO (rezafungin)
- Phase Of Trial
- Phase III
- Fungal free survival sar
- 59.0%
- Fungal free survival rezafungin
- 60.7%
- Potential us market opportunity
- >$2 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.